

Vanta Bioscience to foray into clinical research business

01 August 2018 | News

The company has said in a statement that the clinical research business will begin contributing to the topline in the last quarter of the current financial year. The company is projecting to add revenue of Rs. 250 crore in the fifth year through clinical research services.



Hyderabad-based Vanta Bioscience which provides pre-clinical services has announced its foray into clinical research.

Further to this, the Board of Vanta Bioscience has approved incorporation of a 100% subsidiary in the name of Vanta Clinical Research at Hyderabad. Additionally, the Board has also approved incorporation of a 51% step down subsidiary of the above mentioned company in the name of Vanta Research Solutions at Hyderabad.

The company has said in a statement that the clinical research business will begin contributing to the topline in the last quarter of the current financial year. The company is projecting to add revenue of Rs. 250 crore in the fifth year through clinical research services.

Vanta Bioscience is an emerging, full service preclinical contract research organization, headquartered in the USA and operating out of Chennai, India. Vanta Bioscience is established as a center of excellence for GLP toxicology and safety assessment. It is housed in a new, 56,000 square foot state-of-the-art facility specifically designed for compliance with GLP and AAALAC international guidelines for humane care and use of small animal species involved in Vanta Bioscience studies. The facility is registered with the CPCSEA, Govt. of India and has acquired the OECD GLP Accreditation from the National GLP Monitoring Authority of India, in addition to the AAALAC International Accreditation, joining an elite group of facilities in India. AAALAC certification is valued as the gold standard for animal care and use.